# Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)

> **NCT00405184** · PHASE3 · COMPLETED · sponsor: **CSL Limited** · enrollment: 19 (actual)

## Conditions studied

- Primary Immune Deficiency (PID)

## Interventions

- **DRUG:** IntragamP
- **DRUG:** Ig NextGen 10%

## Key facts

- **NCT ID:** NCT00405184
- **Lead sponsor:** CSL Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2008-07
- **Final completion:** 2008-07
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00405184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00405184, "Ig NextGen 10% in Patients With Primary Immune Deficiency (PID)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00405184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*